| Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 366 (9503), 2087-2106, 2005 | 6172 | 2005 |
| Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ... Annals of oncology 24 (9), 2206-2223, 2013 | 4310 | 2013 |
| Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino, N Wolmark, ... The Lancet 384 (9938), 164-172, 2014 | 4291 | 2014 |
| Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised … L Gianni, T Pienkowski, YH Im, L Roman, LM Tseng, MC Liu, A Lluch, ... The lancet oncology 13 (1), 25-32, 2012 | 2647 | 2012 |
| Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer SM Swain, J Baselga, SB Kim, J Ro, V Semiglazov, M Campone, ... New England journal of medicine 372 (8), 724-734, 2015 | 2275 | 2015 |
| Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ... Annals of oncology 26 (8), 1533-1546, 2015 | 2230 | 2015 |
| Polychemotherapy for early breast cancer: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 352 (9132), 930-942, 1998 | 2159 | 1998 |
| Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 A Goldhirsch, JN Ingle, RD Gelber, AS Coates, B Thürlimann, HJ Senn Annals of oncology 20 (8), 1319-1329, 2009 | 1955 | 2009 |
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial J Baselga, I Bradbury, H Eidtmann, S Di Cosimo, E De Azambuja, C Aura, ... The Lancet 379 (9816), 633-640, 2012 | 1579 | 2012 |
| Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer … L Gianni, W Eiermann, V Semiglazov, A Manikhas, A Lluch, S Tjulandin, ... The Lancet 375 (9712), 377-384, 2010 | 1564 | 2010 |
| De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ... Annals of Oncology 28 (8), 1700-1712, 2017 | 1240 | 2017 |
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo … SM Swain, SB Kim, J Cortés, J Ro, V Semiglazov, M Campone, E Ciruelos, ... The lancet oncology 14 (6), 461-471, 2013 | 1128 | 2013 |
| SYSTEMIC TREATMENT OF EARLY BREAST-CANCER BY HORMONAL, CYTOTOXIC, OR IMMUNE THERAPY-133 RANDOMIZED TRIALS INVOLVING 31000 RECURRENCES AND 24000 DEATHS AMONG 75000 WOMEN. 2. O Abe, R Abe, K Asaishi, K Enomoto, T Hattori, Y Ino, K Kikuchi, ... Lancet 339 (8785), 71-85, 1992 | 1090 | 1992 |
| Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update M Kaufmann, GN Hortobagyi, A Goldhirsch, S Scholl, A Makris, ... Journal of Clinical Oncology 24 (12), 1940-1949, 2006 | 936 | 2006 |
| Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study W Eiermann, S Paepke, J Appfelstaedt, A Llombart-Cussac, J Eremin, ... Annals of oncology 12 (11), 1527-1532, 2001 | 928 | 2001 |
| 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre … L Gianni, T Pienkowski, YH Im, LM Tseng, MC Liu, A Lluch, ... The lancet oncology 17 (6), 791-800, 2016 | 875 | 2016 |
| Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study B Leyland-Jones, V Semiglazov, M Pawlicki, T Pienkowski, S Tjulandin, ... Journal of Clinical Oncology 23 (25), 5960-5972, 2005 | 821 | 2005 |
| Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor–positive breast cancer J Baselga, V Semiglazov, P van Dam, A Manikhas, M Bellet, ... Journal of Clinical Oncology 27 (16), 2630-2637, 2009 | 816 | 2009 |
| Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial L Gianni, U Dafni, RD Gelber, E Azambuja, S Muehlbauer, A Goldhirsch, ... The lancet oncology 12 (3), 236-244, 2011 | 800 | 2011 |
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 … SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ... The Lancet Oncology 21 (4), 519-530, 2020 | 597 | 2020 |
